Trial Profile
A Randomised, Placebo-controlled, Incomplete Block, Three-way Cross-over Study to Evaluate the Effect of Treatment With Repeat Inhaled Doses of GW870086X on the Allergen-induced Early and Late Asthmatic Response in Subjects With Mild Asthma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Aug 2023
Price :
$35
*
At a glance
- Drugs GSK 870086 (Primary) ; Fluticasone propionate
- Indications Asthma
- Focus Biomarker; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 23 Mar 2012 Official title amended as reported by ClinicalTrials.gov.
- 21 Nov 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 21 Nov 2009 Actual end date (Nov 2009) added as reported by ClinicalTrials.gov.